Ross Thomas M. 4
4 · MAXCYTE, INC. · Filed Apr 12, 2023
Insider Transaction Report
Form 4
MAXCYTE, INC.MXCT
Ross Thomas M.
EVP, Global Sales
Transactions
- Exercise/Conversion
Common Stock
2023-04-12$2.14/sh+5,583$11,959→ 5,583 total - Exercise/Conversion
Employee Stock Option (right to buy)
2023-04-10−100→ 27,902 totalExercise: $2.14Exp: 2029-03-04→ Common Stock (100 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2023-04-12−5,583→ 13,868 totalExercise: $2.14Exp: 2029-03-04→ Common Stock (5,583 underlying) - Sale
Common Stock
2023-04-10$5.00/sh−100$500→ 0 total - Sale
Common Stock
2023-04-12$5.00/sh−5,583$27,915→ 0 total - Exercise/Conversion
Common Stock
2023-04-10$2.14/sh+100$214→ 100 total - Exercise/Conversion
Common Stock
2023-04-11$2.14/sh+8,451$18,102→ 8,451 total - Sale
Common Stock
2023-04-11$5.00/sh−8,451$42,255→ 0 total - Exercise/Conversion
Employee Stock Option (right to buy)
2023-04-11−8,451→ 19,451 totalExercise: $2.14Exp: 2029-03-04→ Common Stock (8,451 underlying)
Footnotes (3)
- [F1]The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022.
- [F2]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]This option is fully vested and exercisable.